Hasibe VERDİ, Belgin ATAÇ, Sevinç SARINÇ ULAŞLI, Gaye ULUBAY, Kevser MELEK, Füsun ÖNER EYÜBOĞLU

Kronik obstrüktif akciğer hastalığında tgf-β1 g/a ve tnf-α 308 g/a gen polimorfizmleri ile hava yolu direncinin değerlendirilmesi

Giriş: Kronik obstrüktif akciğer hastalığı (KOAH) tüm dünyada önemli bir mortalite ve morbidite nedenidir. Her ne kadar KOAH için spesifik bir gen bölgesi tanımlanmamış olsa da özellikle inflamatuvar süreçte rol alan tümör nekroz faktörü-al- fa (TNF-α), dönüştürülmüş büyüme faktörü-beta1 (TGF-β1) gibi sitokin genlerine ait bazı polimorfizmlerin KOAH gelişimin- de etkili olabileceği gösterildi. Bu çalışma, KOAH’lı olgularda TGF-β1 G/A ve TNF-α 308 G/A gen polimorfizmleriyle hava yolu direnci artışını değerlendirmek amacıyla yapıldı. Hastalar ve Metod: Çalışmaya toplam 264 olgu dahil edildi (Grup 1; KOAH tanısı almış 75 hasta, Grup 2; en az 10 paket yılı sigara içmiş ancak hava yolu obstrüksiyonu gelişmemiş 139 hasta, Grup 3; sağlıklı 50 birey). Olgulara solunum fonk- siyon testi ve vücut pletismografisiyle hava yolu direnci ölçümü yapıldı. TGF-β1 800 G/A ve TNF-α 308 G/A gen polimor- fizmleri değerlendirildi. İstatistiksel analiz için ki-kare testi, Anova ve korelasyon analizleri kullanıldı. Bulgular: KOAH olguları evrelerine göre TNF-α 308 G/A polimorfizm açısından karşılaştırıldığında istatistiksel olarak an- lamlı fark bulundu (p< 0.05). Evre I olguların 13 (%23.6)’ünün bu polimorfizmi taşıdığı, evre II ve evre III olgularda bu po- limorfizmin olmadığı saptandı. KOAH olguları evrelerine göre TGF-β1 800 G/A polimorfizmi açısından karşılaştırıldığında istatistiksel olarak anlamlı farklılık bulunmadı (p> 0.05). Gruplar arasında TNF-α genotipi ve TGF-β1 genotipi ve TNF-α 308 G/A ve TGF-β1 800 G/A polimorfizm sıklığı açısından farklılık saptanmadı. Ayrıca, hava yolu direnci artmış ve artmamış olgular arasında da TNF-α 308 G/A ve TGF-β1 800 G/A polimorfizmi açısından anlamlı fark bulunmadı. Sonuç: Bu sonuçlar ile TNF-α 308 G/A ve TGF-β1 800 G/A polimorfizmlerinin toplumumuzda KOAH gelişimine ve hava yo- lu direncine katkısının önemli derecede olmadığı öngörülebilir.

Associations between TGF-β1 G/A and TNF-α 308 G/A gene polymorphisms with airway resistance in chronic obstructive pulmonary disease

ntroduction: Chronic obstructive pulmonary disease (COPD) is an important morbidity and mortality cause all over the world. Although specific gene region has not been defined in the pathogenesis of COPD, cytokine gene polymorphisms li- ke tumor necrosis factor-alfa (TNF-α) and transforming growth factor-beta1 (TGF-β1) may contribute to the development of COPD. The aim of the present study was to evaluate the associations between airway resistance with TGF-β1 G/A and TNF- α 308 G/A gene polymorphisms in COPD patients. Patients and Methods: 264 subjects were included to the study (Group 1; 75 COPD patients, Group 2; 139 subjects with at least 10 packet year smoking history without airflow obstruction, Group 3; 50 healthy subjects). Pulmonary function tests and body plethysmography to measure airway resistance were performed to the subjects. TGF-β1 800 G/A and TNF-α 308 G/A gene polymorphisms were evaluated. Chi-square, Anova and correlation analysis were used for statistical analysis. Results: There were significant difference among COPD stages in terms of TNF-α 308 G/A polymorphism (p< 0.05). Thirteen (23.6%) stage 1 COPD patients had TNF-α 308 G/A polymorphism and the other did not have. We did not find statistically significant difference among COPD stages in terms of TGF-β1 800 G/A polymorphism (p> 0.05). TNF-α and TGF-β1 genoty- pes and TNF-α 308 G/A and TGF-β1 800 G/A polymorphisms were not different among study groups. Moreover, no signi- ficant differences betweeen subjects with and without increased airway resistance in terms of TNF-α 308 G/A and TGF-β1 800 G/A polymorphisms were present. Conclusion: These results can suggest the lack of association between TNF-α 308 G/A and TGF-β1 800 G/A gene polymorp- hisms with COPD development and airway resistance in Turkish population.

PDF

___

1. Mathers CD, Loncar D. Projections of global mortality and bur- den of disease from 2002 to 2030. PLoS Med 2006; 3: e442.
2. Petty TL. Chronic obstructive pulmonary disease. In: Hanley ME, Welsh CH (eds). Current Diagnosis and Treatment in Pul- monary Medicine Lange Medical Boks. MacGraw-Hill Compa- nies, 2003: 82-91.
3. Stanford AJ, Weir TD, Pare PD. Genetic risk factors for chronic obstructive pulmonary disease. Eur Respir J 1997; 10: 1380- 91.
4. Barnes PJ, Shapiro SD, Pauwels RA. Chronic obstructive pul- monary disease: molecular and cellular mechanisms. Eur Res- pir J 2003; 22: 672-88.
5. Zhang S, Wang C, Xi B, Li X. Association between the tumour necrosis factor-α -308 G/A polymorphism and chronic obst- ructive pulmonary disease: an update. Respirology 2011; 16: 107-15.
6.Gong Y, Fan L, Wan H, Shi Y, Shi G, Feng Y, et al. Lack of as- sociation between the TGF-β(1) gene and development of COPD in Asians: a case-control study and meta-analysis. Lung 2011; 189: 213-23.
7.Kaminsky DA. Spirometry and related tests. In: Ruppel GL (ed). Manual of Pulmonary Function Testing. 9th ed. Chapter 2, Mosby Elsevier, 2009: 36-89.
8. Global Initiative for chronic obstructive pulmonary disease updated, chapter 1 (definition), 2007: 2-6.
9. Pellegrino R, Viegi G, Brusasco V, Crapo RO, Burgos F, Casa- buri R, et al. Interpretative strategies for lung function tests. Eur Respir J 2005; 26: 948-68.
10. Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Co- ates A, et al; ATS/ERS Task Force. Standardisation of spiro- metry. Eur Respir J 2005; 26: 319-38.
11.Fishman AP, Elias JA, Fishman JA, Grippi MA, Senior RM, Pack AI, et al. Physiological principles of normal lung functi- on. In: Fishman AP (ed). Fishman’s Pulmonary Diseases and Disorders. 4th ed. Vol. I. China: Mc Graw Hill Companies, 2008: 147-60.
12.DuBois AB. Significance of measurement of airway resistance. In: International Symposium on Body Plethysmography, Nij- megen, the Netherlands, 1968. Vol. 4. Progr Res Basel, Swit- zerland: Karger, Res 1969: 109-15.
13.Matthys H, Orth U. Comparative measurements of airway re- sistance. Respiration 1975; 32: 121-34.
14.Murray CJL, Lopez AD. Global health statistics: a compendi- um of incidence, prevalence and mortality estimates for over 200 conditions. Geneva, Switzerland: World Health Organiza- tion, 1996.
15.Kocabaş, A, Hancıoğlu A, Türkyılmaz S, Ünalan T, Umut S, Çakır B, et al. Prevelance of COPD in Adana, Turkey (BOLD- Turkey Study). Proceedings of the American Thoracic Society 2006; 3: A543.
16.Shapiro SD, Snider GL, Rennard SI. Chronic bronchitis and emphysema. In: Mason RJ, Murray JF, Broaddus VC, Nadel JA (eds). Murray and Nadel’s Textbook of Respiratory Medici- ne. 4th ed. Section J-Chapter 36. Vol 1. USA: Elsevier Saun- ders, 2005: 1115-68.
17.Calverley PM, Leggett RJ, McElderry L, Flenley DC. Cigarette smoking and secondary polycythemia in hypoxic cor pulmo- nale. Am Rev Respir Dis 1982; 125: 507-10.
18.Wedzicha JA, Cotes PM, Empey DW, Newland AC, Royston JP, Tam RC. Serum immunoreactive erythropoietin in hypoxic lung disease with and without polycythaemia. Clin Sci 1985; 69: 413-22.
19.Goldsmith JR, Landaw SA. Carbon monoxide and human he- alth. Science 1968; 162: 1352-9.
20. Tanabe N, Ohnishi K, Fukui H, Ohno R. Effect of smoking on the serum concentration of erythropoietin and granulocyte-co- lony stimulating factor. Intern Med 1997; 36: 680-4.
21. Quanjer PH, Tammeling GJ, Cotes JE, Pedersen OF, Peslin R, Yernault JC. Lung volumes and forced ventilatory flows. Eur Respir J Suppl 1993; 16: 5-40.
22. Saryal SB, Karabıyıkoğlu G, Akkoca Ö, Çelik G. Kronik hava- yolları obstrüksiyonunda ventilatuvar parametrelerle hava yolları rezistansı ve iletimi arasındaki ilişki. Solunum Hasta- lıkları 1995; 6: 371-82.
23.Wagner EM, Bleecker ER, Permutt S, Liu MC. Peripheral air- ways resistance in smokers. Am Rev Respir Dis 1992; 146: 92- 5.
24.Pride NB. Airflow resistance. In: Hughes JM, Pride NB (eds). Lung Function Tests: Physiological Principles and Clinical Applications. 1st ed. London: Harcourt Brace and Company Limited, 1999: 27-43.
25.Doershuk CF, Fisher BJ, Matthews LW. Specific airway resis- tance from the perinatal period into adulthood. Alterations in childhood pulmonary disease. Am Rev Respir Dis 1974; 109: 452-7.
26.Dab I, Alexander F. Lung function measured with a whole body plethysmograph: standard values for children and yo ung adults. Acta Paediatr Belg 1979; 32: 259-67.
27.Bisgaard H, Nielsen KG. Plethysmographic measurements of specific airway resistance in young children. Chest 2005; 128: 355-62.
28.Klug B, Bisgaard H. Specific airway resistance, interrupter re- sistance, and respiratory impedance in healthy children aged 2-7 years. Pediatr Pulmonol 1998; 25: 322-31.
29.Stoller JK, Aboussouan LS. Alpha1-antitrypsin deficiency. Lancet 2005; 365: 2225-36.
30.Sakao S, Tatsumi K, Igari H, Shino Y, Shirasava H, Kuriyama T. Association of tumor necrosis factor-alpha gene promoter polymorphism with the presence of chronic obstructive pul- monary disease. Am J Respir Crit Care Med 2001; 163: 420-2.
31.Sakao S, Tatsumi K, Igari I, Watanabe R. Association of tumor necrosis factor-alpha gene promoter polymorphism with low attenuation areas on high-resolution CT in patients with COPD. Chest 2002; 122: 416-20.
32.Chierakul N, Wongwisutikul P, Vejbaesya S, Chotvilaiwan K. Tumor necrosis factor-alpha gene promoter polymorphism is not associated with smoking-related COPD in Thailand. Res- pirology 2005; 10: 36-9.
33. Ishii T, Matsuse T, Teramoto S, Matsui H, Miyao M, Hosoi T, et al. Neither IL-1beta, IL-1 receptor antagonist, nor TNF-alpha polymorphisms are associated with susceptibility to COPD. Respir Med 2000; 94: 847-51.
34. Patuzzo C, Gile LS, Zorzetto M, Trabetti E, Malerba G, Pignatti PF, et al. Tumor necrosis factor gene complex in COPD and dis- seminated bronchiectasis. Chest 2000; 117: 1353-8.
35. Ferrarotti I, Zorzetto M, Beccaria M, Gile LS, Porta R, Ambrosi- no N, et al. Tumour necrosis factor family genes in a phenoty- pe of COPD associated with emphsema. Eur Resp J 2003; 21: 444-9.
36. Küçükaycan M, Van Krugten M, Pennings HJ, Huizinga T, Bu- urman WA, Dentener MA, et al. Tumor necrosis factor-alpha +489G/A gene polymorphism is associated with chronic obst- ructive pulmonary disease. Respir Res 2002; 3: 29.
37. Wu L, Chau J, Young RP, Pokorny V, Mills GD, Hopkins R, et al. Transforming growth factor-beta1 genotype and suscepti- bility to chronic obstructive pulmonary disease. Thorax 2004; 59: 126-9.
38. Celedon JC, Lange C, Raby BA, Litonjua AA, Palmer LJ, De- Meo DL, et al. The transforming growth factor-beta 1 (TGF-β1 gene is associated with chronic obstructive pulmonary dise- ase (COPD). Hum Mol Genet 2004; 13: 1649-56.
39. Su ZG, Wen FQ, Feng YL, Xiao M, Wu XL. Transforming growth factor-beta1 gene polymorphisms associated with chronic obstructive pulmonary disease in Chinese population. Acta Pharmacol Sin 2005; 26: 714-20.
40. Ogawa E, Ruan J, Connett JE, Anthonisen NR, Pare PD, Sand- ford AJ. Transforming growth factor-beta1 polymorphisms, airway responsiveness and lung function decline in smokers. Respir Med 2007; 101: 938-43.